Jose-Carlos Gutiérrez-Ramos
Chief Tech/Sci/R&D Officer bei DANAHER CORPORATION
Vermögen: 4 Mio $ am 31.03.2024
Profil
Dr. Jose Carlos Gutirrez Ramos ist ein unabhängiger Direktor bei Bicycle Therapeutics Plc, ein Chief Science Officer & Senior Vice President bei Danaher Corp., ein President & Chief Executive Officer bei Cogen Immune Medicine, Inc. und ein Chief Executive Officer bei Excaliard Pharmaceuticals, Inc. Er ist Mitglied des Verwaltungsrats von Bicycle Therapeutics Plc. Dr. Gutirrez Ramos war zuvor als Vice President-Drug Discovery bei AbbVie, Inc. tätig, als President, Chief Executive Officer & Director bei Repertoire Immune Medicines, Inc. als unabhängiger Director bei Oryzon Genomics SA, als unabhängiger Director bei Momenta Pharmaceuticals, Inc. als President & Chief Executive Officer bei Synlogic Operating Co, Inc. als President, Chief Executive Officer & Director bei Synlogic, Inc. als SVP-Research & Development bei Pfizer, Inc, ein Senior Vice President bei Avidia, Inc. ein Chief Scientific Officer bei Peptimmune, Inc. ein Mitglied beim Basel Institute for Immunology, ein SVP, Head-BioTherapeutics Research & Development bei Centers for Therapeutic Innovation, ein Chief Scientific Officer bei Genetrix, Inc. ein Senior Vice President bei GlaxoSmithKline AG, ein Assistant Professor bei Harvard University, ein Vice President-Inflammation bei Millennium Pharmaceuticals, Inc. und ein Professor beim National Center for Biotechnology Information. Er war auch im Vorstand von Evelo Biosciences, Inc. Er erhielt seinen Bachelor-Abschluss von der Universidad Complutense de Madrid und einen Doktortitel von der Universidad Autnoma de Madrid.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
DANAHER CORPORATION
0,00% | 01.03.2024 | 12 958 ( 0,00% ) | 3 Mio $ | 31.03.2024 |
02.01.2024 | 16 750 ( 0,06% ) | 417 075 $ | 31.03.2024 | |
EVELO BIOSCIENCES, INC.
0,00% | 08.06.2023 | 500 ( 0,00% ) | 23 $ | 31.03.2024 |
Aktive Positionen von Jose-Carlos Gutiérrez-Ramos
Unternehmen | Position | Beginn |
---|---|---|
DANAHER CORPORATION | Chief Tech/Sci/R&D Officer | 01.01.2021 |
BICYCLE THERAPEUTICS PLC | Director/Board Member | 17.03.2021 |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01.08.2018 |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Jose-Carlos Gutiérrez-Ramos
Unternehmen | Position | Ende |
---|---|---|
EVELO BIOSCIENCES, INC. | Director/Board Member | 20.11.2023 |
ABBVIE INC. | Corporate Officer/Principal | 01.01.2021 |
MOMENTA PHARMACEUTICALS, INC. | Director/Board Member | 01.10.2020 |
EVELO BIOSCIENCES, INC. | Director/Board Member | 25.02.2020 |
ORYZON GENOMICS S.A. | Director/Board Member | 21.02.2020 |
Ausbildung von Jose-Carlos Gutiérrez-Ramos
Universidad Complutense de Madrid | Undergraduate Degree |
Universidad Autónoma de Madrid | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 8 |
---|---|
DANAHER CORPORATION | Health Technology |
PFIZER, INC. | Health Technology |
ABBVIE INC. | Health Technology |
GSK PLC | Health Technology |
ORYZON GENOMICS S.A. | Health Technology |
BICYCLE THERAPEUTICS PLC | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Private Unternehmen | 12 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Avidia, Inc.
Avidia, Inc. Pharmaceuticals: MajorHealth Technology Avidia, Inc. developed pharmaceutical products. The company developed a novel, proprietary class of small therapeutic proteins. The company was headquartered in Mountain View, CA. | Health Technology |
Genetrix, Inc.
Genetrix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Genetrix, Inc. is a genetics testing research company. The private company is based in Scottsdale, AZ. Genetrix was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on May 06, 1996 for $39.20 million. | Commercial Services |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
GlaxoSmithKline AG
GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Health Technology |
National Center for Biotechnology Information | Government |
Centers for Therapeutic Innovation | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Commercial Services |